Safety and efficacy of verinurad, a selective URAT1 inhibitor, for the treatment of patients with gout and/or asymptomatic hyperuricemia in the United States and Japan: Findings from two phase II trials

Verinurad combined with febuxostat in Japanese adults with gout or asymptomatic hyperuricaemia: a phase 2a, open-label study

(2018) Masanari Shiramoto et al.   RHEUMATOLOGY

Pharmacokinetics, pharmacodynamics, and tolerability of verinurad, a selective uric acid reabsorption inhibitor, in healthy Japanese and non-Asian male subjects

(2018) Jesse Hall et al.   Drug Design Development and Therapy

Lesinurad monotherapy in gout patients intolerant to a xanthine oxidase inhibitor: a 6 month phase 3 clinical trial and extension study

(2017) Anne-Kathrin Tausche et al.   RHEUMATOLOGY

Pharmacokinetics, pharmacodynamics, and tolerability of verinurad, a selective uric acid reabsorption inhibitor, in healthy adult male subjects

(2017) Zancong Shen et al.   Drug Design Development and Therapy

Lesinurad, a Selective Uric Acid Reabsorption Inhibitor, in Combination With Febuxostat in Patients With Tophaceous Gout: Findings of a Phase III Clinical Trial

(2017) Nicola Dalbeth et al.   Arthritis & Rheumatology

Discovery and characterization of verinurad, a potent and specific inhibitor of URAT1 for the treatment of hyperuricemia and gout

(2017) Philip K. Tan et al.   Scientific Reports

Lesinurad in combination with allopurinol: results of a phase 2, randomised, double-blind study in patients with gout with an inadequate response to allopurinol

(2016) Fernando Perez-Ruiz et al.   ANNALS OF THE RHEUMATIC DISEASES

Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study)

(2016) Thomas Bardin et al.   ANNALS OF THE RHEUMATIC DISEASES

2016 updated EULAR evidence-based recommendations for the management of gout

(2016) P Richette et al.   ANNALS OF THE RHEUMATIC DISEASES

Serum uric acid levels and the risk of flares among gout patients in a US managed care setting

(2016) Aki Shiozawa et al.   CURRENT MEDICAL RESEARCH AND OPINION

Lesinurad Combined With Allopurinol: A Randomized, Double-Blind, Placebo-Controlled Study in Gout Patients With an Inadequate Response to Standard-of-Care Allopurinol (a US-Based Study)

(2016) Kenneth G. Saag et al.   Arthritis & Rheumatology

Clinical Phenotype Classifications Based on Static Varus Alignment and Varus Thrust in Japanese Patients With Medial Knee Osteoarthritis

(2015) Hirotaka Iijima et al.   Arthritis & Rheumatology

Optimizing current treatment of gout

(2014) Frances Rees et al.   Nature Reviews Rheumatology

Gout treatment: should we aim for rapid crystal dissolution?

(2013) Eliseo Pascual et al.   ANNALS OF THE RHEUMATIC DISEASES

2012 American College of Rheumatology guidelines for management of gout. Part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia

(2012) Dinesh Khanna et al.   ARTHRITIS CARE & RESEARCH

The effect of gout on health-related quality of life, work productivity, resource use and clinical outcomes among patients with hypertension

(2012) Marco daCosta DiBonaventura et al.   Expert Review of Pharmacoeconomics & Outcomes Research

Difficult-to-Treat Gouty Arthritis

(2011) Naomi Schlesinger   DRUGS

Japanese Guideline for the Management of Hyperuricemia and Gout: Second Edition

(2011) Hisashi Yamanaka   NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS

Risk factors associated with renal lithiasis during uricosuric treatment of hyperuricemia in patients with Gout

(2010) Fernando Perez-Ruiz et al.   ARTHRITIS CARE & RESEARCH

A Benefit-Risk Assessment of Benzbromarone in the Treatment of Gout

(2009) Ming-Han H Lee et al.   DRUG SAFETY

Treating to target: a strategy to cure gout

(2009) F. Perez-Ruiz   RHEUMATOLOGY